U.S. policy responses to calls for the medical use of Cannabis

Yale Journal of Biology and Medicine

Volumn 88, Issue 3, 2015, Pages 257-264

  Hall, Wayne ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabis; Marijuana; Medical use

Indexed keywords

CANNABINOID; CODEINE; DRONABINOL; MEDICAL CANNABIS; NABILONE; NABIXIMOLS; PLACEBO;

ANALGESIA; ANTIEMETIC ACTIVITY; CANNABIS USE; CHRONIC DISEASE; COMMERCIAL PHENOMENA; DECREASED APPETITE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG SAFETY; EMERGENCY HEALTH SERVICE; GOVERNMENT; HEALTH CARE POLICY; HUMAN; INTRACTABLE EPILEPSY; LEGAL ASPECT; MEDICAL PROFESSION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN; PRESCRIPTION; PSYCHOSIS; REVIEW; UNITED STATES; WASTING SYNDROME; CALIFORNIA; DRUG CONTROL; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; RISK ASSESSMENT; TRENDS;

CALIFORNIA; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; FEDERAL GOVERNMENT; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; MEDICAL MARIJUANA; RISK ASSESSMENT; UNITED STATES;

EID: 84940743755     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press; 1986.
2. Grinspoon L, Bakalar J. Marihuana, the forbidden medicine. New Haven: Yale University Press; 1993.
3. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag. 2001;6(2):80-91.
4. Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012;87(2):172-86.
5. Hall WD, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383-91.
6. Iversen L. The science of marijuana. 2nd ed. Oxford: Oxford University Press; 2007.
7. Institute of Medicine. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press; 1999.
8. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-46.
9. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1- 25.
10. Di Marzo V, PetrocEllis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med. 2006;57:553-74.
11. Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J. 2001;323(7303):16-21.
12. Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LMQ, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17(5):431-43.
13. Navari RM. Pharmacological management of chemotherapyinduced nausea and vomiting: focus on recent developments. Drugs. 2009;69(5):515-33.
14. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013;4:CD005175.
15. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319-34.
16. Christie MJ. Opioid and cannabinoid receptors: friends with benefits or just close friends? Br J Pharmacol. 2006;148(4):385-6.
17. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10(8):1353-68.
18. Podda G, Constantinescu CS. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opin Biol Ther. 2012;12(11):1517-31.
19. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517-26.
20. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664-9.
21. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17-24.
22. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791-802.
23. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175-85.
24. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;6:CD009270.
25. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2012;133(1):79-97.
26. Dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2014;40(2):135-43.
27. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669-78.
28. Fernandez O. Advances in the management of multiple sclerosis spasticity: recent clinical trials. Eur Neurol. 2014;72(Suppl 1):9-11.
29. Vachová M, Novotná A, Mares J, Taláb R, Fiedler J, Lauder H, et al. A multicentre, double-blind, randomised, parallelgroup, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis. Journal of Multiple Sclerosis. 2014;1(122):2.
30. Hall WD. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction. 2015;110(1):19-35.
31. Hall WD, Swift W. The policy implications of cannabis dependence. In: Roffman RA, Stephens RS, editors. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press; 2006. p. 315-39.
32. Anthony JC. The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, editors. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press; 2006. p. 58-105.
33. AusPAR: Nabiximols. Australian Public Assessment Report. Australian Government Department of Health, Therapeutic Goods Administration [Internet]. [cited 2013]. Available from: https://www.tga.gov.au/auspar/auspar-nabiximols.
34. Degenhardt L, Hall WD. Is cannabis a contributory cause of psychosis? Can J Psychiatry. 2006;51(9):556-65.
35. Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M, et al. Cannabis use and risk of psychotic or affec- tive mental health outcomes: A systematic review. Lancet. 2007;370(9584):319-28.
36. Hall WD, Degenhardt L. What are the policy implications of the evidence on cannabis and psychosis? Can J Psychiatry. 2006;51(9):566-74.
37. Hall WD, Degenhardt L. Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. Addiction. 2007;102(11):1685-8.
38. Jouanjus E, Lapeyre-Mestre M, Micallef J. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014;3(2):e000638.
39. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187-90.
40. Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. 2015;24(1):15-31.
41. Grotenhermen F. Cannabinoids for therapeutic use: designing systems to increase efficacy and reliability. Am J Drug Deliv. 2004;2(4):229-40.
42. Hall WD, Degenhardt L, Lynskey MT. The health and psychological effects of cannabis use. Canberra: Commonwealth Department of Health and Aged Care; 2001.
43. Cohen SP. Cannabinoids for chronic pain. BMJ. 2008;336(7637):167-8.
44. Taylor S. Remedicalising cannabis: science, medicine and policy, 1973 to the early twenty-first century. Unpublished doctoral thesis. London: School of Hygiene and Tropical Medicine; 2010.
45. Sativex. GW Pharmaceuticals [Internet]. Available from: http://www.gwpharm.com/Sativex.aspx.
46. Galston W, Dionne EJ. The new politics of marijuana legalization: why opinion is changing. Governance Studies at Brookings [Internet]. [cited 2013]. Available from: http://www.brookings.edu/research/papers/2013/05/29-politics- marijuana-legalization-galston-dionne.
47. Pacula RL, Chriqui JF, Reichman DA, Terry-McElrath Y. State medical marijuana laws: understanding the laws and their limitations. J Public Health Policy. 2002;23(4):411-37.
48. Conboy JR. Smoke screen: America's drug policy and medical marijuana. Food Drug Law J. 2000;55(4):601-17.
49. Medical marijuana pros and cons. 23 legal medical marijuana states and DC: law, fees and possession limits. Pro- Con.org [Internet]. [cited 2015]. Available from: http://medicalmarijuana.procon.org/view.resource.php?resourceID= 00881.
50. Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J Policy Anal Manage. 2015;34(1):7-31.
51. Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med. 2010;362(16):1453-7.
52. Cohen PJ. Medical marijuana 2010: it's time to fix the regulatory vacuum. J Law Med Ethics. 2010;38(3):654-66.
53. Regan T. Joint ventures: inside America's almost legal marijuana industry. New York: Wiley; 2011.
54. Barnes RE. Reefer madness: legal and moral issues surrounding the medical prescription of marijuana. Bioethics. 2000;14(1):16-41.
55. Cohen PJ. Medical marijuana, compassionate use, and public policy: expert opinion or vox populi? Hastings Cent Rep. 2006;36(3):19-22.
56. Eddy M. Medical marijuana: review and analysis of federal and state policies. Washington, DC: Congressional Research Service; 2009.
57. Samuels D. Dr Kush: how medical marijuana is transforming the pot industry. New Yorker [Internet]. [cited 2008]. Available from: http://www.newyorkerest.com/2008/drkush- how-medical-marijuana-is-transforming-the-pot-industry/.
58. O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J. 2007;4:16.
59. Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43(2):128-35.
60. Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 2015;34(2):141-6.
61. Teesson M, Degenhardt L, Lynskey M, Hall WD. The relationships between substance use and mental health problems: evidence from longitudinal studies. In: Stockwell T, Gruenwald PJ, Toumbourou JW, Loxley W, editors. Preventing harmful substance use: the evidence base for policy and practice. Chichester, UK: John Wiley; 2005. p. 43-51.
62. Bogdanoski T. Accommodating the medical use of marijuana: surveying the differing legal approaches in Australia, the United States and Canada. J Law Med. 2010;17(4):508-31.
63. Room R, Fischer B, Hall WD, Lenton S, Reuter P. Cannabis policy: moving beyond stalemate. Oxford: Oxford University Press; 2010.
64. Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol. 2013;69(8):1575-80.
65. Garvey T, Yeh BT. State legalization of recreational marijuana: selected legal issues. Washington, DC: Congressional Research Office; 2014.
66. Retail marijuana 2013. Colorado Department of Public Health and Environment [Internet]. [cited 2015]. Available from: https://www.colorado.gov/pacific/cdphe/retail-marijuana.
67. I-502 Implementation 2014. Washington State Liquor Control Board [Internet]. [cited 2015]. Available from: http://www.liq.wa.gov/marijuana/I-502.
68. Associated Press. Colorado medical marijuana rules are vulnerable to change. Herald-Tribune [Internet]. [cited 2015]. Available from: http://marijuana.heraldtribune.com/2015/01/04/coloradomedical- marijuana-rules-vulnerable-change/.
69. Hickenlooper GJW. Experimenting with pot: the state of Colorado's legalization of marijuana. Milbank Q. 2014;92(2):243-9.
70. Basu R. Colorado's marijuana law has brought tourists and tax revenues. Des Moines Register [Internet]. [cited 2014]. Available from: http://www.desmoinesregister.com/story/opinion/columnists/ rekha-basu/2014/08/17/colorados-marijuana-law-broughttourists- tax-revenues/14178219/.
71. Caulkins J, Hawken A, Kilmer B, Kleiman M. Marijuana legalization: what everyone needs to know. New York: Oxford University Press; 2012.